HLTH - Snapshot
HLTH SQUARE

VanEck Blog & Insights

Register Now

VanEck Global Global Healthcare Leaders ETF HLTH

Fund description: HLTH gives investors exposure to a diversified portfolio of the largest international companies from the global healthcare sector. HLTH aims to provide investment returns before fees and other costs which track the performance of the Index. 

Index description: The MarketGrader Developed Markets (ex-Australia) Health Care Index consists of 50 fundamentally sound companies with the best growth at a reasonable price (GARP) attributes in the healthcare sector from developed markets excluding Australia.

Management style:  Replication

Country of domicile: Australia

 as at 25-May-22

  • Exchange

    ASX

  • ASX code

    HLTH

  • Bloomberg index code

    MGHCAUNR

  • Index provider

    MarketGrader

  • NAV1

    $10.10

  • Units outstanding1

    8,000,381

  • Net assets1

    $80.8M

  • Number of holdings1

    50

  • Inception date2

    08-Sep-20

  • ASX commencement

    10-Sep-20
1As of the close of the previous trading day.
2The date the ETF was seeded prior to quotation on ASX.

as at 25-May-22

*The NAV is generally calculated daily after all markets are closed for that day based on the closing price of the securities on the relevant foreign stock exchange. The NAV is then converted to AUD based on the relevant London WM Reuters 4pm exchange rate. This means, due to Australia’s time zone, that the NAV will generally not be updated until around 1pm next business day. 

 

Invest Now

Key benefits

Global growth opportunity
A sector with significant growth potential due to shifting global demographics, social changes, research & development and innovation supporting increased demand in healthcare-related products and services

A portfolio of global healthcare leaders comprising the most fundamentally strong companies
Invests in 50 fundamentally sound and attractively valued companies with the best growth prospects in the healthcare sector

Targeted exposure and diversification
A portfolio which targets focused exposure to healthcare and offers true diversification by equally weighting across companies

Trading information

  • ASX code

    HLTH

  • IRESS code

    HLTH.AXW

  • Units outstanding

    8,000,381

  • ISIN

    AU0000102683

Fees and other costs  

  • Management costs p.a.

    0.45%

Key risks

An investment in the ETF carries risks associated with: ASX trading time differences, financial markets generally, individual company management, industry sectors, foreign currency, currency hedging, country or sector concentration, political, regulatory and tax risks, fund operations, liquidity and tracking an index. See the PDS for details.

Prices as at  25-May-22

NAV/
Last trade		 Volume:
30-day avg/
Previous day		 Daily change: NAV/
Last trade		 YTD change:
NAV/
Last trade		 Premium/
Discount		 Premium/
Discount
Distribution charts		 NAV &
Premium /Discount
History		 NAV
Chart
HLTH $10.10
$10.09		 54,908
37,620		 $-0.01 / -0.08%
$0.02 / +0.20%		 -18.32%
-18.76%
 $-0.01
-0.13%

Performance history (%) View all ETFs » View all indices »

1 Mth 3 Mths 6 Mths 1 Yr 3 Yrs p.a. 5 Yrs p.a. 10 Yrs p.a. ETF Inception p.a.
Price return -4.92 -8.16 -12.57 -1.84 -- -- -- 1.90
Income return 0.00 0.00 0.00 0.35 -- -- -- 0.22
Total return -4.92 -8.16 -12.57 -1.49 -- -- -- 2.12
Index (MGHCAUNR) -4.91 -8.06 -12.39 -1.06 11.94 14.00 20.30 2.59
1 Mth 3 Mths 6 Mths 1 Yr 3 Yrs p.a. 5 Yrs p.a. 10 Yrs p.a. ETF Inception p.a.
Price return -0.01 -12.77 -10.86 5.99 -- -- -- 5.36
Income return 0.00 0.00 0.00 0.38 -- -- -- 0.24
Total return -0.01 -12.77 -10.86 6.37 -- -- -- 5.60
Index (MGHCAUNR) 0.06 -12.65 -10.65 6.86 13.05 16.60 20.90 6.10
The tables above show past performance of the ETF from 8 September 2020. Index performance shown prior to 14 August 2020 is simulated based on the current Index methodology. Results are calculated to the last business day of the month and assume immediate reinvestment of dividends. ETF results are net of management fees and costs incurred in the fund, but before brokerage fees or bid/ask spreads incurred when investors buy/sell on the ASX. Returns for periods longer than one year are annualised. Past performance is not a reliable indicator of current or future performance which may be lower or higher.
The S&P Global 1200 Health Care Index (“Benchmark”) is shown for comparison purposes as it is the widely recognised benchmark used to measure the performance of the health care industry globally, weighted by market capitalisation. HLTH’s index measures the performance of 50 fundamentally sound companies with the best growth at a reasonable price (GARP) attributes in the health care industry from developed markets excluding Australia, weighted equally at rebalance. It has fewer companies and different country and industry allocations than the Benchmark. Click here for more details.

Top ten holdings (%) View all daily holdings » as at 30-Apr-22

No. of holdings: 50
Holding name
Ticker
 No. of securities held Market value % of Fund
net assets
NOVARTIS AG
NOVN SW
 19,873 2,492,362 2.89
SONOVA HOLDING AG
SOON SW
 4,521 2,328,032 2.70
VERTEX PHARMACEUTICALS INC
VRTX US
 5,331 2,049,582 2.38
MERCK & CO INC
MRK US
 16,285 2,032,388 2.36
HALOZYME THERAPEUTICS INC
HALO US
 35,273 1,980,430 2.30
NOVO NORDISK A/S
NOVOB DC
 12,054 1,953,991 2.27
BRISTOL-MYERS SQUIBB CO
BMY US
 18,180 1,925,573 2.23
INCYTE CORP
INCY US
 18,088 1,907,938 2.21
REGENERON PHARMACEUTICALS INC
REGN US
 2,056 1,906,888 2.21
JOHNSON & JOHNSON
JNJ US
 7,457 1,893,604 2.20
Top ten total (%) 23.75
These are not recommendations to buy or to sell any security.

Country weightings (%) as at 30-Apr-22

  • Country

    Weightings (%)

  • United States

    53.6

  • Switzerland

    13.8

  • France

    5.8

  • Japan

    5.4

  • Italy

    4.0

  • South Korea

    3.8

  • China

    3.6

  • Denmark

    2.3

  • Belgium

    2.2

  • Germany

    2.0

  • Luxembourg

    1.9

  • New Zealand

    1.5

  • Other/Cash

    0.1

  • Total

    100.0

Sub-sector weightings (%) as at 30-Apr-22

  • Sector

    Weightings (%)

  • Pharmaceuticals

    25.7

  • Biotechnology

    25.0

  • Life Sciences Tools & Services

    22.4

  • Health Care Equipment & Supplies

    20.9

  • Health Care Providers & Services

    5.9

  • Other/Cash

    0.1

  • Total

    100.0